Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
Do you recommend pharmacological ADT for a patient with hypogonadism with unfavorable or high risk prostate cancer whose testosterone was castrate (<20) without supplementation?
Is this degree of hypogonadism sufficient to omit leuprolide?
Related Questions
For patients who progress to mCRPC on ADT+ARSI started in mCSPC setting, do you continue the ARSI if patients have had a mixed response?
Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
What dose of prednisone do you prefer when treating CRPC vs CSPC with abiraterone?
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC after progression on first line combinations?
How would you approach treating a patient with prostate adenocarcinoma with urothelial features?
How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?
Does a negative staging PSMA PET in a patient with biopsy-proven recurrent prostatic adenocarcinoma change your management?